Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 4/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.49 |
| ▸ | BCR | P11274 | 4/20 | 0.49 |
| ▸ | RXRA | P19793 | 2/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | RXRG | P48443 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | PGR | P06401 | 2/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26784208 | 0.88 | ABL1 (0.62) | ABL1ABCB1BCRRXRARXRB | |
| SCHEMBL25365883 | 0.83 | ABL1 (0.44) | ABL1ABCB1BCRRXRARXRB | |
| SCHEMBL16585054 | 0.82 | KIF11 (0.52) | RXRARXRBRXRGERN1KIF11 | |
| SCHEMBL26798799 | 0.81 | NOS3 (0.46) | ABL1ABCB1BCRRXRARXRB | |
| SCHEMBL12386386 | 0.80 | NPC1 (0.57) | ABL1ABCB1BCRERN1MTNR1A | |
| SCHEMBL13079694 | 0.80 | NPC1 (0.57) | ABL1ABCB1BCRERN1MTNR1A | |
| SCHEMBL30516644 | 0.79 | KDM1A (0.55) | NPC1CASP3RAB9ASENP8SENP7 | |
| SCHEMBL25367014 | 0.79 | KDM1A (0.55) | NPC1CASP3RAB9ASENP8SENP7 | |
| SCHEMBL7236573 | 0.79 | FFAR1 (0.55) | RXRARXRBRXRG | |
| SCHEMBL21589900 | 0.79 | ABL1 (0.50) | ABL1ABCB1BCRRXRAPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2023-11-16 | — | — | US | disclosed |
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | PTGER1, PTGIR, PTGDR2 | ABL1 3553/4885ABCB1 3380/4885BCR 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.